Immunophenotypic predictive profiling of BRCA1-associated breast cancer

Virchows Archiv

Volumn 458, Issue 1, 2011, Pages 55-64

  Domagala, Pawel ^a   Huzarski, Tomasz ^a   Lubinski, Jan ^a   Gugala, Karol ^b   Domagala, Wenancjusz ^c  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b Regional Oncology Hospital   (Poland)

^c NONE

Author keywords

BRCA1; Breast cancer; c kit; EGFR; Estrogen receptor; PARP 1

Indexed keywords

BRCA1 PROTEIN; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROGESTERONE; PROGESTERONE RECEPTOR; STEM CELL FACTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER SIZE; DNA DETERMINATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ADULT; AGED; BRCA1 PROTEIN; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOPHENOTYPING; MIDDLE AGED; POLY(ADP-RIBOSE) POLYMERASES; PREDICTIVE VALUE OF TESTS; PROTEIN ARRAY ANALYSIS; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 78651339074     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00428-010-0988-3     Document Type: Article

References (53)

1. R Wooster BL Weber 2003 Breast and ovarian cancer N Engl J Med 348 2339 2347 1:CAS:528:DC%2BD3sXkt1Kktrc%3D 10.1056/NEJMra012284 12788999 (Pubitemid 36638109)
2. J Fasano F Muggia 2009 Breast cancer arising in a BRCA-mutated background: therapeutic implications from an animal model and drug development Ann Oncol 20 609 614 1:STN:280:DC%2BD1M3jt1eqtw%3D%3D 10.1093/annonc/mdn669 19150941
3. EA Comen M Robson 2010 Inhibition of poly(ADP)-ribose polymerase as a therapeutic strategy for breast cancer Oncology (Williston Park) 24 55 62
4. A Bosch P Eroles R Zaragoza JR Vina A Lluch 2010 Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research Cancer Treat Rev 36 206 215 1:CAS:528:DC%2BC3cXksFChsbo%3D 10.1016/j.ctrv.2009.12.002 20060649
5. SR Lakhani MJ Van De Vijver J Jacquemier TJ Anderson PP Osin L McGuffog DF Easton 2002 The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2 J Clin Oncol 20 2310 2318 1:CAS:528:DC%2BD38XktVKrs7o%3D 10.1200/JCO.2002.09.023 11981002 (Pubitemid 34441658)
6. SR Lakhani JS Reis-Filho L Fulford F Penault-Llorca M van der Vijver S Parry T Bishop J Benitez C Rivas YJ Bignon J Chang-Claude U Hamann CJ Cornelisse P Devilee MW Beckmann C Nestle-Kramling PA Daly N Haites J Varley F Lalloo G Evans C Maugard H Meijers-Heijboer JG Klijn E Olah BA Gusterson S Pilotti P Radice S Scherneck H Sobol J Jacquemier T Wagner J Peto MR Stratton L McGuffog DF Easton Breast Cancer Linkage Consortium 2005 Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype Clin Cancer Res 11 5175 5180 1:CAS:528:DC%2BD2MXmt12qtbk%3D 10.1158/1078-0432.CCR-04- 2424 16033833 (Pubitemid 41003703)
7. CT Brekelmans C Seynaeve M Menke-Pluymers HT Bruggenwirth MM Tilanus-Linthorst CC Bartels M Kriege AN van Geel CM Crepin JC Blom H Meijers-Heijboer JG Klijn 2006 Survival and prognostic factors in BRCA1-associated breast cancer Ann Oncol 17 391 400 1:STN:280: DC%2BD287ht1OksQ%3D%3D 10.1093/annonc/mdj095 16322115 (Pubitemid 43329574)
8. M Graeser K Bosse M Brosig C Engel RK Schmutzler German Consortium for Hereditary Breast and Ovarian Cancer 2009 Association of hormone receptor status with grading, age of onset, and tumor size in BRCA1-associated breast cancer Virchows Arch 454 519 524 1:CAS:528:DC%2BD1MXlt1SmtLg%3D 10.1007/s00428-009- 0760-8 19381686
9. N Tung Y Wang LC Collins J Kaplan H Li R Gelman AH Comander B Gallagher K Fetten K Krag KA Stoeckert RD Legare D Sgroi PD Ryan JE Garber SJ Schnitt 2010 Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features Breast Cancer Res 12 R12 10.1186/bcr2478 20149218
10. B Gorski C Cybulski T Huzarski T Byrski J Gronwald A Jakubowska M Stawicka S Gozdecka-Grodecka M Szwiec K Urbanski J Mitus E Marczyk J Dziuba P Wandzel D Surdyka O Haus H Janiszewska T Debniak A Toloczko-Grabarek K Medrek B Masojc M Mierzejewski E Kowalska SA Narod J Lubinski 2005 Breast cancer predisposing alleles in Poland Breast Cancer Res Treat 92 19 24 1:STN:280:DC%2BD2MzivVWqtQ%3D%3D 10.1007/s10549-005-1409-1 15980987 (Pubitemid 40875074)
11. CW Elston IO Ellis 1991 Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up Histopathology 19 403 410 1:STN:280: DyaK38%2FpvVSltw%3D%3D 10.1111/j.1365-2559.1991.tb00229.x 1757079
12. S Detre G Saclani Jotti M Dowsett 1995 A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas J Clin Pathol 48 876 878 1:STN:280:DyaK28%2Fps1arsQ%3D%3D 10.1136/jcp.48.9.876 7490328
13. AC Wolff ME Hammond JN Schwartz KL Hagerty DC Allred RJ Cote M Dowsett PL Fitzgibbons WM Hanna A Langer LM McShane S Paik MD Pegram EA Perez MF Press A Rhodes C Sturgeon SE Taube R Tubbs GH Vance M van de Vijver TM Wheeler DF Hayes American Society of Clinical Oncology/College of American Pathologists 2007 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer Arch Pathol Lab Med 131 18 43 1:CAS:528:DC%2BD2sXhsVOmu74%3D 19548375 (Pubitemid 46174133)
14. ME Hammond DF Hayes M Dowsett DC Allred KL Hagerty S Badve PL Fitzgibbons G Francis NS Goldstein M Hayes DG Hicks S Lester R Love PB Mangu L McShane K Miller CK Osborne S Paik J Perlmutter A Rhodes H Sasano JN Schwartz FC Sweep S Taube EE Torlakovic P Valenstein G Viale D Visscher T Wheeler RB Williams JL Wittliff AC Wolff 2010 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer Arch Pathol Lab Med 134 907 922 20524868
15. P Ulivi W Zoli L Medri D Amadori L Saragoni F Barbanti D Calistri R Silvestrini 2004 c-kit and SCF expression in normal and tumor breast tissue Breast Cancer Res Treat 83 33 42 1:CAS:528:DC%2BD2cXnvVOj 10.1023/B:BREA. 0000010694.35023.9e 14997053 (Pubitemid 38141891)
16. T Byrski T Huzarski R Dent J Gronwald D Zuziak C Cybulski J Kladny B Gorski J Lubinski SA Narod 2009 Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients Breast Cancer Res Treat 115 359 363 1:CAS:528:DC%2BD1MXmsVGjsrs%3D 10.1007/s10549-008-0128-9 18649131
17. A Bhattacharyya US Ear BH Koller RR Weichselbaum DK Bishop 2000 The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin J Biol Chem 275 23899 23903 1:CAS:528:DC%2BD3cXls12lsrk%3D 10.1074/jbc.C000276200 10843985 (Pubitemid 30624678)
18. V Schreiber F Dantzer JC Ame G de Murcia 2006 Poly(ADP-ribose): novel functions for an old molecule Nat Rev Mol Cell Biol 7 517 528 1:CAS:528:DC%2BD28Xms1Ohsb4%3D 10.1038/nrm1963 16829982 (Pubitemid 44036457)
19. H Farmer N McCabe CJ Lord AN Tutt DA Johnson TB Richardson M Santarosa KJ Dillon I Hickson C Knights NM Martin SP Jackson GC Smith A Ashworth 2005 Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature 434 917 921 1:CAS:528:DC%2BD2MXjtFOmsrc%3D 10.1038/nature03445 15829967 (Pubitemid 40559006)
20. HE Bryant N Schultz HD Thomas KM Parker D Flower E Lopez S Kyle M Meuth NJ Curtin T Helleday 2005 Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase Nature 434 913 917 1:CAS:528:DC%2BD2MXjtFOmsrY%3D 10.1038/nature03443 15829966 (Pubitemid 40559005)
21. PC Fong DS Boss TA Yap A Tutt P Wu M Mergui-Roelvink P Mortimer H Swaisland A Lau MJ O'Connor A Ashworth J Carmichael SB Kaye JH Schellens JS de Bono 2009 Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers N Engl J Med 361 123 134 1:CAS:528:DC%2BD1MXosVKrtrw%3D 10.1056/NEJMoa0900212 19553641
22. A Tutt M Robson JE Garber SM Domchek MW Audeh JN Weitzel M Friedlander B Arun N Loman RK Schmutzler A Wardley G Mitchell H Earl M Wickens J Carmichael 2010 Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial Lancet 376 235 244 1:CAS:528:DC%2BC3cXpt1KktLc%3D 10.1016/S0140-6736(10)60892-6 20609467
23. Z Fu C Fenselau 2005 Proteomic evidence for roles for nucleolin and poly[ADP-ribosyl] transferase in drug resistance J Proteome Res 4 1583 1591 1:CAS:528:DC%2BD2MXhtVWmtrfF 10.1021/pr0501158 16212410 (Pubitemid 41464784)
24. JM de Murcia C Niedergang C Trucco M Ricoul B Dutrillaux M Mark FJ Oliver M Masson A Dierich M LeMeur C Walztinger P Chambon G de Murcia 1997 Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells Proc Natl Acad Sci U S A 94 7303 7307 10.1073/pnas.94.14.7303 9207086 (Pubitemid 27345310)
25. C Trucco FJ Oliver G de Murcia J Menissier-de Murcia 1998 DNA repair defect in poly(ADP-ribose) polymerase-deficient cell lines Nucleic Acids Res 26 2644 2649 1:CAS:528:DyaK1cXktFalur4%3D 10.1093/nar/26.11.2644 9592149 (Pubitemid 28297377)
26. CK Osborne 1998 Steroid hormone receptors in breast cancer management Breast Cancer Res Treat 51 227 238 1:STN:280:DyaK1M7msFCmsg%3D%3D 10.1023/A:1006132427948 10068081 (Pubitemid 29054556)
27. MC King S Wieand K Hale M Lee T Walsh K Owens J Tait L Ford BK Dunn J Costantino L Wickerham N Wolmark B Fisher National Surgical Adjuvant Breast and Bowel Project 2001 Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial JAMA 286 2251 2256 1:CAS:528:DC%2BD3MXosFCktr8%3D 10.1001/jama.286.18.2251 11710890 (Pubitemid 33063147)
28. AM Hosey JJ Gorski MM Murray JE Quinn WY Chung GE Stewart CR James SM Farragher JM Mulligan AN Scott PA Dervan PG Johnston FJ Couch PA Daly E Kay A McCann PB Mullan DP Harkin 2007 Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer J Natl Cancer Inst 99 1683 1694 1:CAS:528:DC%2BD1cXkslyluw%3D%3D 10.1093/jnci/djm207 18000219 (Pubitemid 351767217)
29. JS Ross EA Slodkowska WF Symmans L Pusztai PM Ravdin GN Hortobagyi 2009 The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine Oncologist 14 320 368 1:CAS:528:DC%2BD1MXlvFOhtLw%3D 10.1634/theoncologist.2008-0230 19346299
30. F Milanezi S Carvalho FC Schmitt 2008 EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy Expert Rev Mol Diagn 8 417 434 1:CAS:528:DC%2BD1cXotFOqt78%3D 10.1586/14737159.8.4.417 18598224 (Pubitemid 351962088)
31. E Lim F Vaillant D Wu NC Forrest B Pal AH Hart ML Asselin-Labat DE Gyorki T Ward A Partanen F Feleppa LI Huschtscha HJ Thorne kConFab SB Fox M Yan JD French MA Brown GK Smyth JE Visvader GJ Lindeman 2009 Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers Nat Med 15 907 913 1:CAS:528:DC%2BD1MXpt1Onsro%3D 10.1038/nm.2000 19648928
32. OT Johannsson I Idvall C Anderson A Borg RB Barkardottir V Egilsson H Olsson 1997 Tumour biological features of BRCA1-induced breast and ovarian cancer Eur J Cancer 33 362 371 1:STN:280:DyaK2szgtVCqtQ%3D%3D 10.1016/S0959-8049(97)89007-7 9155518 (Pubitemid 27168060)
33. BJ Lynch JA Holden SS Buys SL Neuhausen DK Gaffney 1998 Pathobiologic characteristics of hereditary breast cancer Hum Pathol 29 1140 1144 1:STN:280:DyaK1cvlt12itw%3D%3D 10.1016/S0046-8177(98)90427-0 9781655 (Pubitemid 28467537)
34. P Osin BA Gusterson E Philp J Waller J Bartek J Peto T Crook 1998 Predicted anti-oestrogen resistance in BRCA-associated familial breast cancers Eur J Cancer 34 1683 1686 1:CAS:528:DyaK1cXntlShtbg%3D 10.1016/S0959-8049(98) 00248-2 9893652 (Pubitemid 28474219)
35. F Eisinger C Nogues JM Guinebretiere JP Peyrat VJ Bardou T Noguchi P Vennin R Sauvan R Lidereau D Birnbaum J Jacquemier H Sobol 1999 Novel indications for BRCA1 screening using individual clinical and morphological features Int J Cancer 84 263 267 1:STN:280:DyaK1M3pslOmtg%3D%3D 10.1002/(SICI)1097-0215(19990621)84:3<263::AID-IJC11>3.0.CO;2-G 10371344 (Pubitemid 29256752)
36. SA Vaziri LM Krumroy P Elson GT Budd G Darlington J Myles RR Tubbs G Casey 2001 Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis Clin Cancer Res 7 1937 1945 1:CAS:528:DC%2BD3MXlslalur4%3D 11448907
37. TA Grushko MA Blackwood PL Schumm FG Hagos MO Adeyanju MD Feldman MO Sanders BL Weber OI Olopade 2002 Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers Cancer Res 62 1481 1488 1:CAS:528:DC%2BD38Xit1Khu78%3D 11888924
38. LA Quenneville KA Phillips H Ozcelik RK Parkes JA Knight PJ Goodwin IL Andrulis FP O'Malley 2002 HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry Cancer 95 2068 2075 1:CAS:528: DC%2BD38XptVKntL0%3D 10.1002/cncr.10949 12412159 (Pubitemid 35253367)
39. JR Goffin PO Chappuis LR Begin N Wong JS Brunet N Hamel AJ Paradis J Boyd WD Foulkes 2003 Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data Cancer 97 527 536 1:CAS:528:DC%2BD3sXhtlKhtbg%3D 10.1002/cncr.11080 12548593 (Pubitemid 36125829)
40. WD Foulkes K Metcalfe P Sun WM Hanna HT Lynch P Ghadirian N Tung OI Olopade BL Weber J McLennan IA Olivotto LR Begin SA Narod 2004 Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type Clin Cancer Res 10 2029 2034 1:CAS:528: DC%2BD2cXisVGlu7c%3D 10.1158/1078-0432.CCR-03-1061 15041722 (Pubitemid 38375563)
41. J Lubinski B Gorski T Huzarski T Byrski J Gronwald P Serrano-Fernandez W Domagala M Chosia M Ucinski E Grzybowska D Lange B Maka A Mackiewicz A Karczewska J Breborowicz K Lamperska M Stawicka S Gozdecka-Grodecka M Bebenek D Sorokin A Wojnar O Haus J Sir T Mierzwa S Niepsuj K Gugala S Gozdz J Sygut B Kozak-Klonowska B Musiatowicz M Posmyk R Kordek M Morawiec O Zambrano B Wasko L Fudali J Skret D Surdyka K Urbanski J Mitus J Rys M Szwiec A Rozmiarek I Dziuba P Wandzel R Wisniowski C Szczylik A Kozak W Kozlowski SA Narod 2006 BRCA1-positive breast cancers in young women from Poland Breast Cancer Res Treat 99 71 76 1:CAS:528:DC%2BD28XnslShsL8%3D 10.1007/s10549-006-9182-3 16541315 (Pubitemid 44168605)
42. RA Oldenburg K Kroeze-Jansema H Meijers-Heijboer CJ van Asperen N Hoogerbrugge I van Leeuwen HF Vasen AM Cleton-Jansen J Kraan JJ Houwing-Duistermaat H Morreau CJ Cornelisse P Devilee 2006 Characterization of familial non-BRCA1/2 breast tumors by loss of heterozygosity and immunophenotyping Clin Cancer Res 12 1693 1700 1:CAS:528:DC%2BD28Xis1Cjs78%3D 10.1158/1078-0432.CCR-05-2230 16551851
43. P van der Groep A Bouter R van der Zanden I Siccama FH Menko JJ Gille C van Kalken E van der Wall RH Verheijen PJ van Diest 2006 Distinction between hereditary and sporadic breast cancer on the basis of clinicopathological data J Clin Pathol 59 611 617 10.1136/jcp.2005.032151 16603649 (Pubitemid 43886045)
44. AI Hagen AM Bofin B Ytterhus LO Maehle KH Kjellevold HO Myhre P Moller PE Lonning 2007 Amplification of TOP2A and HER-2 genes in breast cancers occurring in patients harbouring BRCA1 germline mutations Acta Oncol 46 199 203 1:CAS:528:DC%2BD2sXjs1GlsLg%3D 10.1080/02841860600949552 17453369
45. E Honrado A Osorio RL Milne MF Paz L Melchor A Cascon M Urioste A Cazorla O Diez E Lerma M Esteller J Palacios J Benitez 2007 Immunohistochemical classification of non-BRCA1/2 tumors identifies different groups that demonstrate the heterogeneity of BRCAX families Mod Pathol 20 1298 1306 1:CAS:528:DC%2BD2sXhtlSmtbnF 10.1038/modpathol.3800969 17885670 (Pubitemid 350126855)
46. DP Atchley CT Albarracin A Lopez V Valero CI Amos AM Gonzalez-Angulo GN Hortobagyi BK Arun 2008 Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer J Clin Oncol 26 4282 4288 10.1200/JCO.2008.16.6231 18779615
47. K Aaltonen C Blomqvist RM Amini H Eerola K Aittomaki P Heikkila H Nevanlinna 2008 Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers Clin Cancer Res 14 1976 1983 1:CAS:528:DC%2BD1cXkt1akur4%3D 10.1158/1078-0432.CCR-07-4100 18381935 (Pubitemid 351551106)
48. MM Litwiniuk K Roznowski V Filas DD Godlewski M Stawicka R Kaleta J Breborowicz 2008 Expression of estrogen receptor beta in the breast carcinoma of BRCA1 mutation carriers BMC Cancer 8 100 10.1186/1471-2407-8-100 18405391 (Pubitemid 351727843)
49. LC Collins A Martyniak MJ Kandel ZK Stadler S Masciari A Miron AL Richardson SJ Schnitt JE Garber 2009 Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers Am J Surg Pathol 33 1093 1097 10.1097/PAS.0b013e3181b7cb7a 19390427
50. DG Evans F Lalloo A Cramer EA Jones F Knox E Amir A Howell 2009 Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing J Med Genet 46 811 817 1:STN:280:DC%2BD1MjptlWlug%3D%3D 10.1136/jmg.2009.067850 19542080
51. A Kwong LP Wong HN Wong FB Law EK Ng YH Tang WK Chan DT Suen C Choi LS Ho KH Kwan M Poon TT Wong K Chan SW Chan MW Ying WC Chan ES Ma JM Ford DW West 2009 Clinical and pathological characteristics of Chinese patients with BRCA related breast cancer Hugo J 3 63 76 10.1007/s11568-010-9136-z 20535403
52. E Manie A Vincent-Salomon J Lehmann-Che G Pierron E Turpin M Warcoin N Gruel I Lebigot X Sastre-Garau R Lidereau A Remenieras J Feunteun O Delattre H de The D Stoppa-Lyonnet MH Stern 2009 High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors Cancer Res 69 663 671 1:CAS:528:DC%2BD1MXltFSgtg%3D%3D 10.1158/0008-5472.CAN-08-1560 19147582
53. SA Joosse EH van Beers IH Tielen H Horlings JL Peterse N Hoogerbrugge MJ Ligtenberg LF Wessels P Axwijk S Verhoef FB Hogervorst PM Nederlof 2009 Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH Breast Cancer Res Treat 116 479 489 1:CAS:528:DC%2BD1MXhtFGmtrzF 10.1007/s10549-008-0117-z 18704682